Tranexamic acid
- Generic Name
- Tranexamic acid
- Brand Names
- Cyklokapron, Lysteda
- Drug Type
- Small Molecule
- Chemical Formula
- C8H15NO2
- CAS Number
- 1197-18-8
- Unique Ingredient Identifier
- 6T84R30KC1
- Background
Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.
It was first patented in 1957 and received its initial US approval in 1986.
- Indication
Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleeding following tooth extraction.
- Associated Conditions
- Bleeding, Heavy Menstrual Bleeding, Hereditary Angioedema (HAE)
- Associated Therapies
- -
Tranexamic Acid Use to Reduce Blood Transfusion in Pediatric Cancer Patients Undergoing Limb Salvage Procedure
- Conditions
- Interventions
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT04410042
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Topical Tranexamic Acid After Intravitreal Injections
- Conditions
- Interventions
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2020-05-26
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 100
- Registration Number
- NCT04400916
Tranexamic Acid Reduce Blood Loss in Meningioma Resection
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Chiang Mai University
- Target Recruit Count
- 44
- Registration Number
- NCT04386642
- Locations
- 🇹🇭
Chiang Mai University, Chiang Mai, Thailand
Use of Tranexamic Acid in Facial Fillers
- Conditions
- Interventions
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- University of Wisconsin, Madison
- Registration Number
- NCT04373603
- Locations
- 🇺🇸
University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States
Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Jun Zhang
- Target Recruit Count
- 151
- Registration Number
- NCT04360629
- Locations
- 🇨🇳
Shanghai Cancer Center, Fudan University, Shanghai, Shanghai, China
Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2021-04-23
- Lead Sponsor
- University of Alabama at Birmingham
- Registration Number
- NCT04338126
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Tranexamic Acid Infusion During Elective Spine Surgery
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Albany Medical College
- Target Recruit Count
- 65
- Registration Number
- NCT04312880
- Locations
- 🇺🇸
Albany Medical Center, Albany, New York, United States
Prophylactic Tranexamic Acid During Minimally Invasive Myomectomies
- Conditions
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Eastern Virginia Medical School
- Target Recruit Count
- 50
- Registration Number
- NCT04311073
- Locations
- 🇺🇸
EasternVMC, Norfolk, Virginia, United States
Tranexamic Acid in Chinese Elderly Patients With Intertrochanteric Fracture RCT
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 120
- Registration Number
- NCT04290884
- Locations
- 🇭🇰
Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong
TXA in Spinal Fusion
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Catherine R. Olinger
- Target Recruit Count
- 123
- Registration Number
- NCT04272606
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.